Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of NNC0662-0419 in Obesity
NCT07639021Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 2
01
Overview
Phase 2, randomised trial of NNC0662-0419 in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of gastrointestinal adverse events at 39 weeks. Started Jun 2026; status: active, not recruiting.
02
Drugs
NNC0662-0419
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07639021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639021.